05 March 2021 | News
Moderna’s mRNA-1273 to reach South Korea by the second quarter of 2021
Photo Credit: Freepik
GC Pharma has announced that it will support Moderna and the government of the Republic of Korea in the distribution of 40 million doses of COVID-19 Vaccine Moderna.
Moderna’s vaccine candidate against COVID-19, to support South Korea’s aim of providing vaccines to the public in a timely manner, subject to necessary local regulatory approvals. This arrangement is part of GC Pharma’s agreements with Moderna and the government of the Republic of Korea.
The Korea Diseases Control and Prevention Agency previously announced that it will import 40 million doses of COVID-19 Vaccine Moderna in Korea from the second quarter of 2021.
Under the terms of its agreement with Moderna, GC pharma is responsible for local regulatory activities, and under the terms of its agreement with the Korean government, GC Pharma, with support of the Korean government authorities, is responsible for distribution activities in South Korea.
“We are proud to be partnering with the government and Moderna to support the distribution of crucial vaccines to the South Korean public,” said EC Huh, Ph.D, President of GC Pharma. “Safeguarding global citizens remains our top priority. At GC pharma, with using our industry know-how, we are also exploring multiple ways to specifically help those impacted by COVID-19 and ensure preparedness for future public health emergencies.”